Key result
Prophylactic antithrombotic therapy with stanozolol resulted in acute venous thrombosis in 2 of 3 patients, suggesting it is not a suitable prophylactic agent for this condition.
Why the study?
Does prophylactic stanozolol prevent venous thrombosis in patients with familial antithrombin III deficiency?
Case Report (n=3)
Does prophylactic stanozolol prevent venous thrombosis in patients with familial antithrombin III deficiency?
Stanozolol is ineffective and potentially unsafe as a prophylactic antithrombotic agent in patients with familial antithrombin III deficiency.
Stanozolol warrants caution in antithrombin III deficiency; case-level data leave open safer prophylactic options.
Three patients with familial antithrombin III deficiency underwent a trial of prophylactic antithrombotic therapy with stanozolol. An increase in plasma fibrinolytic activity and antithrombin III was seen. Acute venous thrombosis occurred in two patients; in the first patient thrombosis was precipitated by venography but in the second no precipitating factor was found. Our experience suggests that stanozolol is not a suitable prophylactic agent in patients with familial antithrombin III deficiency.
No takes yet. Share an insight, caveat, or question.
Winter et al. (1984) conducted a case report in Familial antithrombin III deficiency (n=3). Stanozolol was evaluated on Acute venous thrombosis. Prophylactic antithrombotic therapy with stanozolol resulted in acute venous thrombosis in 2 of 3 patients, suggesting it is not a suitable prophylactic agent for this condition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: